Skip to main content

Advertisement

Table 2 Treatment responses of 134 non-small cell lung cancer patients with brain metastases

From: Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

  All (N = 134) Gefitinib (N = 62) Erlotinib (N = 49) Afatinib (N = 23) p value
Treatment response .053
 PR 100 (74.6%) 49 (79.4%) 34 (69.4%) 17 (73.9%)  
 SD 26 (19.4%) 12 (19.0%) 12 (24.5%) 2 (8.7%)  
 PD 8 (6.0%) 1 (1.6%) 3 (6.1%) 4 (17.4%)  
Intracranial response .208
 CR 56 (41.8%) 21 (33.9%) 23 (46.9%) 12 (52.2%)  
 PR 26 (19.4%) 12 (19.4%) 11 (22.4%) 3 (13.0%)  
 SD 48 (35.8%) 28 (45.2%) 14 (28.6%) 6 (26.1%)  
 PD 4 (3.0%) 1 (1.6%) 1 (2.0%) 2 (8.7%)  
PD location .055
 Intracranial only 32 (23.9%) 16 (27.0%) 10 (20.4%) 6 (26.1%)  
 Extracranial only 73 (54.5%) 40 (63.5%) 22 (44.9%) 11 (47.8%)  
 Both 13 (9.7%) 4 (6.3%) 6 (12.2%) 3 (13.0%)  
Common adverse effects (≥ grade 2)
 Skin rash or itching 4 (3.0%) 1 (1.6%) 1 (2.0%) 2 (8.7%) .164
 Diarrhea 1 (0.7%) 0 (0.0%) 0 (0.0%) 1 (4.3%) .115
 Paronychia 2 (1.5%) 0 (0.0%) 1 (2.0%) 1 (4.3%) .005
Median PFS (months) [95% CI] 11.4 [9.30 to 13.30] 12.1 [9.00 to 14.50] 10.6 [8.80 to 40.60] 10.4 [7.50 to 17.20] .783a
Time to intracranial PD (months) [95% CI] 23.6 [17.20 to 30.10] 23.6 [17.00 to 30.10] 27.8 [11.30 to 27.80] 17.2 [10.40 to 19.00] .729a
Median OS (months) [95% CI) 36.9 [29.10 to 60.00] 38.2 [29.10 to 60.00] NAb 29.6 [24.80 to 33.00] .695a
  1. aLog-rank test
  2. bThe median overall survival (OS) of the erlotinib group could not be computed. Instead, the median OS of the erlotinib group was 36.9 months (95% CI 19.90 to 36.90) if the Kaplan-Meier survival curves for 60 months were calculated